17/01/2023at 09:59

Novo Nordisk renounces orphan drug title for potential blockbuster

At the end of 2022, Novo decided to relinquish the European orphan drug designation for its antibody treatment, concizumab. The candidate has previously been proclaimed a potential blockbuster.

Ludovic Helfgott, head of Rare Disease at Novo Nordisk, has previously heralded concizumab as a potential blockbuster | Photo: Pr / Novo Nordisk

by christopher due karlsson, translated by daniel pedersen

In December, Novo Nordisk chose to give up a number of regulatory advantages tied to antibody concizumab for the treatment of hemophilia A and B, according to the European Medicines Agency’s (EMA) website.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Novo Holdings invests in US-based gene-editing company
For subscribers
Novo Nordisk has three biopharma blockbusters on the way
FDA approves Novo Nordisk's Rybelsus as first-line treatment option
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Antibiotic Dicillin has infected Danish and Icelandic patients Antibiotikummet Dicillin har smittet både danskere og islændinge med multiresistente bakterier, som patienterne sandsynligvis skal leve med resten af livet. | Foto: Lægemiddelstyrelsen / Pr

Pharma & biotech

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Sandoz ends its collaboration with the secret CMO that made the contaminated antibiotic product and cannot rule out other drugs could be infected with multi-resistant bacteria.

For subscribers

Både danskere og islændinge har nu multiresistente bakterier i kroppen efter at have spist antibiotikummet Dicillin. | Foto: Lægemiddelstyrelsen / Pr

Other

Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

For subscribers

Pharma & biotech

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

For subscribers

Pharma & biotech

Zealand Pharma presents positive early-stage results for weight-loss candidate

For subscribers

Pharma & biotech

Genmab promotes senior VP for strategy to executive management

For subscribers

Medtech

Ambu wins European approval of two fifth-generation bronchoscopes

For subscribers

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Sandoz ends its collaboration with the secret CMO that made the contaminated antibiotic product and cannot rule out other drugs could be infected with multi-resistant bacteria.

For subscribers

Pharma & biotech

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

Despite promising results, one analyst thinks patients will have to wait for higher doses of diabetes pill Rybelsus until 2025.

For subscribers

Pharma & biotech

Obesity drug hit makes Novo Nordisk more valuable than Nestle

The Danish drugmaker has climbed from seventh to second place of Europe’s most valuable firms in just two years.

For subscribers

Novo Nordisk renounces orphan drug title for potential blockbuster

Read the whole article

With your free trial you get:

Get full access for you and your coworkers

Related articles:

Novo Holdings invests in US-based gene-editing company

Novo Nordisk has three biopharma blockbusters on the way

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Sign up for our newsletter

Front page now

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

Zealand Pharma presents positive early-stage results for weight-loss candidate

Genmab promotes senior VP for strategy to executive management

Ambu wins European approval of two fifth-generation bronchoscopes

Further reading

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

Obesity drug hit makes Novo Nordisk more valuable than Nestle

Jobs